Maribavir Synthesis and Purification for Higher Yield and Purity

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing syntheses of maribavir, an antiviral medication for cytomegalovirus infection, suffer from low overall yields and impurities, which affect the quality and safety of the drug product.

Innovation Solution

An improved synthesis of maribavir is developed, incorporating specific reaction conditions and purification methods to enhance yield and reduce impurities, focusing on the production of polymorphic Form VI and controlling particle size distribution for better bioavailability and formulation into tablets.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If existing synthesis methods are used, then maribavir can be produced, but the overall yield is low (27-49%) and impurities are generated

Engineering Contradiction:
Improveoverall yieldVSAvoidimpurities
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The synthesis is divided into modular stages with intermediate purification steps. The process segments the conversion of 2-bromo-5,6-dichlorobenzimidazole through multiple protected intermediates to final maribavir product, allowing impurity removal at each stage rather than dealing with cumulative impurities in a single step.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

Protecting groups are installed on functional groups before the main coupling reactions occur. This preliminary protection prevents unwanted side reactions and impurity formation during subsequent steps, ensuring higher purity of the final product.

Inventive Principle:
Principle #10Preliminary action

2Manufacturing precision

If multiple synthesis steps are performed, then maribavir structure can be achieved, but the number of steps increases process complexity

Engineering Contradiction:
Improvestructural accuracyVSAvoidsynthesis process complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

Multiple transformation steps are combined into telescoped sequences where reaction mixtures are carried forward without full isolation. This merging of steps reduces the number of discrete operations while maintaining the required structural precision through controlled reaction conditions.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The synthesis employs universal protecting group strategies and standardized coupling methodologies that can be applied across different intermediate transformations. This multi-functionality reduces process complexity by using repeatable protocols rather than developing unique conditions for each step.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Productivity

If yield is increased to 45% or higher, then productivity improves, but specific reaction conditions and purification methods must be precisely controlled

Engineering Contradiction:
Improveoverall yieldVSAvoidreaction condition control
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The process incorporates monitoring and control mechanisms to track reaction progress and purity levels. This feedback allows adjustment of conditions during the synthesis to maintain high yield while ensuring product quality, preventing deviation that would reduce efficiency.

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

Optimized reaction parameters such as temperature, solvent composition, and reagent ratios are established for each transformation step. These controlled parameter changes enable the process to achieve high yields by maximizing reaction efficiency while minimizing side product formation.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS20260076945A1Viral inhibitors, the synthesis thereof, and intermediates thereto
Publication Date: 2026.03.19 TAKEDA PHARMA CO LTD
  • US20260076945A1 patent drawing
  • US20260076945A1 patent drawing
  • US20260076945A1 patent drawing

AI summary

The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir.